Oxaliplatin Kalceks

Oxaliplatin, the active ingredient in Oxaliplatin Kalceks, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer and other solid tumours, typically in adult patients. GNH USA supplies Oxaliplatin Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Kalceks is a platinum‑based chemotherapeutic that interferes with DNA replication in rapidly growing cancer cells. - Colorectal cancer: improves overall treatment outcomes when used in combination regimens. - Gastric cancer: contributes to tumour shrinkage as part of multi‑drug protocols. - Pancreatic cancer: used in combination therapies to enhance response rates. - Ovarian cancer : aids in disease control when combined with taxanes. - Advanced solid tumours : provides clinical benefit in selected treatment‑resistant cases.

Oxaliplatin Kalceks may induce a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often reversible after treatment. - Diarrhoea: loose stools that may require supportive care. - Fatigue: generalised tiredness during therapy cycles. - Thrombocytopenia: reduced platelet count, increasing bleed risk. - Elevated liver enzymes: transient rise in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, bronchospasm or anaphylaxis. - Acute neurotoxicity: sudden onset of muscle cramps or jaw tightness. - Persistent peripheral neuropathy: long‑term sensory deficits. - Hemolytic‑type reactions: rapid drop in red blood cells. - Cardiac arrhythmias: irregular heart rhythm requiring monitoring. - Renal impairment: acute kidney injury in susceptible patients.

When handling Oxaliplatin Kalceks, clinicians should observe specific safety measures to minimise risks to patients and staff. - Pre‑treatment assessment: evaluate renal and hepatic function, and review baseline neuropathy. - Hydration status: ensure adequate intravenous fluids to reduce renal toxicity. - Concomitant neurotoxic drugs: avoid or adjust doses of other agents that may worsen neuropathy. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist. - Monitoring: perform regular complete blood counts and liver function tests during therapy. - Store at below 25°C: keep in the original packaging, protect from light and moisture.

Oxaliplatin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney injury. - Anticoagulants (warfarin, heparin): heighten bleeding risk when thrombocytopenia occurs. - High‑dose vitamin C: may reduce platinum‑DNA binding efficacy.

Moderate Interactions (Monitor Closely): - Other neurotoxic chemotherapy (e.g., paclitaxel): may amplify peripheral neuropathy. - CYP450 inducers (rifampicin, carbamazepine): potential modest‑level        decrease  the  met‑   ...